Elizabeth A. Maher

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Magnetic Resonance Spectroscopy of Cystathionine and 2‐Hydroxyglutarate in Brain Tumors

  NMR in Biomedicine · 2025-11-25

• IMG-89. Volumetric (3D) compared with traditional bidirectional (2D) assessment in patients with Grade 2, isocitrate dehydrogenase 1/2 mutant (mIDH1/2) glioma receiving vorasidenib or placebo in the Phase 3 INDIGO trial

  Neuro-Oncology · 2025-11-01

• IMG-99. Volumetric tumor growth rate (TGR) modeling predicts clinical outcomes in patients with Grade 2, isocitrate dehydrogenase 1/2 mutant (mIDH1/2) glioma receiving vorasidenib or placebo in the Phase 3 INDIGO trial

  Neuro-Oncology · 2025-11-01

• Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trial

  The Lancet Oncology · 2025-10-29 · 16 citations

• OS09.4.A EARLY TUMOR VOLUME CHANGES PREDICT CLINICAL OUTCOMES IN MIDH1/2 GLIOMA: POST-HOC RESULTS FROM THE PHASE 3 INDIGO TRIAL

  Neuro-Oncology · 2025-10-01

• Magnetic Resonance Spectroscopy of 2‐Hydroxyglutarate and Glycine in Adult Subjects With Brainstem Gliomas

  NMR in Biomedicine · 2025-09-30 · 2 citations

• Integrating CNS-active therapy with stereotactic radiotherapy for brain metastases: comparative outcomes of PULSAR and FSRTPreprint

  medRxiv · 2025-09-12

• TE optimization for J‐difference editing of 2‐hydroxyglutarate at 3T

  Magnetic Resonance in Medicine · 2025-05-20 · 1 citations

• Comparative Outcomes of Standard Radiation Therapy and 5-Fraction Adaptive Stereotactic Radiation Therapy in Newly Diagnosed Glioblastoma: A Propensity Score–Matched Analysis

  Advances in Radiation Oncology · 2025-05-18 · 3 citations

• Epidermal growth factor receptor and Ink4a/Arf: Convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis

  Cancer Cell · 2024-12-01 · 30 citations

• 10309- ACT-18 A PHASE 1, RANDOMIZED, PERIOPERATIVE TRIAL OF VORASIDENIB AND IVOSIDENIB IN DIFFUSE GLIOMA WITH AN IDH1 MUTATION: UPDATED RESULTS

  Neuro-Oncology Advances · 2024-11-29

• Serine de novo synthesis in glioma patients studied through 13C isotopomer analysis

  Proceedings on CD-ROM - International Society for Magnetic Resonance in Medicine. Scientific Meeting and Exhibition/Proceedings of the International Society for Magnetic Resonance in Medicine, Scientific Meeting and Exhibition · 2024-11-26

• ProFit-1D for quantifying J-difference edited data at 3T

  Proceedings on CD-ROM - International Society for Magnetic Resonance in Medicine. Scientific Meeting and Exhibition/Proceedings of the International Society for Magnetic Resonance in Medicine, Scientific Meeting and Exhibition · 2024-11-26

• CTNI-53. A GLOBAL, RANDOMIZED, DOUBLE-BLINDED, PHASE 3 STUDY OF VORASIDENIB VERSUS PLACEBO IN PATIENTS WITH ADULT-TYPE DIFFUSE GLIOMA WITH AN IDH1/2 MUTATION (INDIGO): UPDATED EFFICACY RESULTS

  Neuro-Oncology · 2024-11-01 · 7 citations

• Glioblastoma

  Elsevier eBooks · 2024-10-11 · 3 citations

• List of Contributors

  Elsevier eBooks · 2024-10-11

• ProFit-1D for quantifying J-difference edited data at 3TPreprint

  bioRxiv (Cold Spring Harbor Laboratory) · 2024-10-11 · 1 citations